<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048268</url>
  </required_header>
  <id_info>
    <org_study_id>GIP HYPO (MC)</org_study_id>
    <nct_id>NCT01048268</nct_id>
  </id_info>
  <brief_title>Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?</brief_title>
  <official_title>Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether glucose-dependent insulinotropic
      polypeptide (GIP) has a stabilizing function on the blood glucose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to investigate the effect of GIP on the glucagon secretion during
      hyper-, eu- and hypoglycemia in healthy volunteers, patients with type 1 diabetes mellitus
      and patients with type 2 diabetes mellitus.

      From this, we will evaluate GIP's role as blood sugar stabilizer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in glucagon secretion quantified as the difference in plasma glucagon concentration and incremental baseline-subtracted area under the curve (AUC) for plasma glucagon</measure>
    <time_frame>-10, 0, 5, 10, 20, 30, 45, 60 and 90 minutes at each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference between the amount of infused glucose and the insulin responses</measure>
    <time_frame>will be measured at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Type 1 diabetes mellitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes mellitus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose-dependent insulinotropic polypeptide</intervention_name>
    <description>For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.
For the following 40 minutes the volunteers will receive 2 pmol/kg body weight</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with Type 1 diabetes mellitus</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>copy GIP infusion rates</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with Type 1 diabetes mellitus</arm_group_label>
    <arm_group_label>Patients with type 2 diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians with T1DM (diagnosed according to WHO's criteria) without residual beta
             cell function (arginine test without increase in c-peptide) in treatment with long
             acting insulin OR

          -  Caucasians with non-insulin treated T2DM (diagnosed according to WHO's criteria) OR

          -  Caucasians without first degree relative with diabetes mellitus, with normal fasting
             plasma glucose and glucose tolerance along with negative islet and GAD-65
             autoantibodies AND

          -  Normal hemoglobin

          -  Informed consent

        Exclusion criteria:

          -  Unwillingness to participate or the wish to leave the present study

          -  HbA1c &gt; 9 %

          -  Liver disease (ALAT or ASAT &gt; 2 times normal value)

          -  Diabetic nephropathy (serum creatinin &gt; 130 microM and/or albuminury)

          -  Proliferative diabetic retinopathy (anamnetic)

          -  Atherosclerotic heart disease or heart failure (NYHA group III and IV)

          -  Anemia

          -  Treatment with medicine which cannot be paused for 12 hours

          -  Pregnancy and/or breast feeding

          -  Fasting plasma glucose &gt; 15 mM on the day of the experiment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip K Knop, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine F' laboratory</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen County</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>July 10, 2015</last_update_submitted>
  <last_update_submitted_qc>July 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Mikkel Christensen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>T1DM</keyword>
  <keyword>T2DM</keyword>
  <keyword>GIP</keyword>
  <keyword>Glucose-dependent insulinotropic polypeptide</keyword>
  <keyword>Incretin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

